+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Lipid Disorder Treatment Market 2020-2026

  • PDF Icon


  • August 2020
  • Region: Global
  • Orion Market Research Private Limited
  • ID: 5148154
Global Lipid Disorder Treatment Market Size, Share & Trends Analysis Report By Indication (Hypercholesterolemia, Dysbetalipoproteinemia, Familial Combined Hyperlipidemia, and Others), By Product Type (Atorvastatin, Simvastatin, Pravastatin, Rosuvastatin, Lovastatin, and Other), By Distribution Channel (Hospital & Clinics, Retail Pharmacies, and Online Pharmacies), Forecast Period (2020-2026).

The global lipid disorder treatment market is anticipated to grow at a CAGR of 7.5% during the forecast period. Lipid disorder is a condition where patient's bodies either have high levels of low-density lipoprotein (LDL) cholesterol, triglycerides, or both. The diagnosis of lipid disorder is done by routine blood check-ups. The raising smoking and consumption of alcohol across the globe are driving the increasing cases of lipid disorder which in turn will fuel the lipid disorder treatment market.

The global lipid disorder treatment market is segmented based on the indication, product type, and distribution channel. Based on the indication, the market is sub-segmented into hypercholesterolemia, dysbetalipoproteinemia, familial combined hyperlipidemia, and others. Based on product type, the market is sub-divided into atorvastatin, simvastatin, pravastatin, rosuvastatin, lovastatin, and others. Further, based on the distribution channel, the market is sub-segmented into hospitals & clinics, retail pharmacies, and online pharmacies.

The global lipid disorder treatment market is further segmented based on geography including North America, Europe, Asia-Pacific, and the Rest of the World. Asia Pacific is expected to show significant growth in the market during the forecast period. The growth in the region is owing to the growing cases of obesity and various other lifestyle disorders.

The key players of the global lipid disorder treatment market include Avanti Polar Lipids, ESPERION Therapeutics, Inc., Ionis Pharmaceuticals, Inc., Micelle BioPharma, Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including merger & acquisition, collaborations with government, funding, new drug launches, and various other advancements to stay competitive in the market. For instance, in February 2019, Novartis AG has overtaken the responsibility of the development and commercialization of TQJ230 across the globe from Akcea Therapeutics.

Research Methodology:

The market study of the global lipid disorder treatment market is incorporated by extensive primary and secondary research. Secondary research has been conducted to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for the drug manufacturers, hospitals & clinics, insurance companies, government organizations, research institutes and other related industries for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, products offered by the companies, and future market opportunities. The report will serve as a source for a 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation:

1. Global Lipid Disorder Treatment Market Research and Analysis by Indication
2. Global Lipid Disorder Treatment Market Research and Analysis by Product Type
3. Global Lipid Disorder Treatment Market Research and Analysis by Distribution Channel.

The Report Covers:
  • Comprehensive research methodology of the global lipid disorder treatment market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global lipid disorder treatment market.
  • Insights about market determinants which are stimulating the global lipid disorder treatment market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Business Functions and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. AstraZeneca Plc Overview Financial Analysis SWOT Analysis Recent Developments
3.3.2. Pfizer Inc. Overview Financial Analysis SWOT Analysis Recent Developments
3.3.3. Ionis Pharmaceuticals, Inc. Overview Financial Analysis SWOT Analysis Recent Developments
3.3.4. Merck & Co. Inc. Overview Financial Analysis SWOT Analysis Recent Developments
3.3.5. Novartis AG Overview Financial Analysis SWOT Analysis Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.1. Opportunities
5. Market Segmentation
5.1. Global Lipid Disorder Treatment Market by Indication
5.1.1. Hypercholesterolemia
5.1.2. Dysbetalipoproteinemia
5.1.3. Familial Combined Hyperlipidemia
5.1.4. Others
5.2. Global Lipid Disorder Treatment Market by Product Type
5.2.1. Atorvastatin
5.2.2. Simvastatin
5.2.3. Pravastatin
5.2.4. Rosuvastatin
5.2.5. Lovastatin
5.2.6. Other
5.3. Global Lipid Disorder Treatment Market by Distribution Channel
5.3.1. Hospital & Clinics
5.3.2. Retail Pharmacies
5.3.3. Online Pharmacies
6. Regional Analysis
6.1. North America
6.1.1. US
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Abbott Laboratories
7.2. Alnylam Pharmaceuticals, Inc.
7.3. Amarin Corp.
7.4. AstraZeneca Plc
7.5. Avanti Polar Lipids, Inc.
7.6. Cadila Healthcare Ltd.
7.7. Eli Lilly and Co.
7.8. ESPERION Therapeutics, Inc.
7.9. Ionis Pharmaceuticals, Inc.
7.10. Merck & Co. Inc.
7.11. Micelle BioPharma, Inc.
7.12. Moderna, Inc.
7.13. Novartis AG
7.14. Otsuka Pharmaceutical Co., Ltd.
7.15. Pfizer Inc.
7.16. Poxel SA
7.17. Roivant Sciences Ltd.
7.18. Sanofi SA
7.19. Sumitomo Dainippon Pharma Co., Ltd
7.20. Sun Pharmaceutical Industries Ltd.
7.21. Teva Pharmaceutical Industries Ltd.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abbott Laboratories
  • Alnylam Pharmaceuticals, Inc.
  • Amarin Corp.
  • Astrazeneca Plc
  • Avanti Polar Lipids, Inc.
  • Cadila Healthcare Ltd.
  • Eli Lilly and Co.
  • ESPERION Therapeutics, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Merck & Co. Inc.
  • Micelle BioPharma, Inc.
  • Moderna, Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Poxel SA
  • Roivant Sciences Ltd.
  • Sanofi SA
  • Sumitomo Dainippon Pharma Co., Ltd
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.